TomislavDragovichMDPhD

Gastrointestinal Cancer, Hematologic Oncology

Professor (Adj) of Medical Oncology, U. Of Texas MD Anderson Cancer Center; Division Chief, Hematology-Oncology and Director of Research, Banner MD Anderson Cancer Center, Arizona

Join to view full profile

Dr. Dragovich is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Dragovich's full profile

Already have an account?

Office
1301 Palm Ave Ste 600
Jacksonville, FL 32207
Phone+1 904-202-7300

Fax+1 904-202-7433

Education & Training

University of ChicagoFellowship, Hematology and Medical Oncology, 1997 - 2000
Louis A Weiss Memorial HospitalResidency, Internal Medicine, 1994 - 1997
University of Belgrade Faculty of MedicineClass of 1988

Certifications & Licensure

AZ State Medical License 2000 - 2026
FL State Medical License 2024 - 2026
IL State Medical License 1997 - 2002
American Board of Internal Medicine Medical Oncology

Clinical Trials

Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction Cancer Start of enrollment: 2002 Jun 01
Completed
Phase 2
PTK787 in Patients With Advanced Metastatic Pancreatic Adenocarcinoma Start of enrollment: 2005 Dec 01
Completed
Phase 2
S9304A Study of Protein Expression in Tumor Tissue Samples From Patients With Stage II or Stage III Rectal Cancer Enrolled in Clinical Trial SWOG-9304 Start of enrollment: 2009 Feb 01
Completed
PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer Start of enrollment: 2013 May 14
Completed
Phase 2
Project Survival-Prospective Biomarker Discovery Start of enrollment: 2016 Mar 01
Active, not recruiting
Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC Start of enrollment: 2019 May 01
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

86 citations
Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resect...
Charles S. Fuchs, Donna Niedzwiecki, Harvey J. Mamon, J. E. Tepper, Xing Ye
Journal of Clinical Oncology. 2017-10-04
18 citations
A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancre...
Daneng Li, Shubham Pant, David P. Ryan, Daniel A. Laheru, Nathan Bahary
Pancreatology. 2014-09-01
46 citations
Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001)
Tomislav Dragovich, Daniel A. Laheru, Farshid Dayyani, Vanessa Bolejack, Lon Smith
Cancer Chemotherapy and Pharmacology. 2014-06-18

Press Mentions

Banner MD Anderson Launches Landmark Research ExpansionFebruary 11th, 2022

Grant Support

Clinical Trials CoreNational Cancer Institute2007–2011
Treatment Of Hypoxia Resistance In Pancreatic Cancer - ClinicalNational Cancer Institute2005–2009
Core -- Clinical ResourcesNational Cancer Institute2002